NPI: 1447227947 · DENVER, CO 80246 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/02/2006
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 03/02/2006 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 3,765 | $200K |
| 2019 | 2,904 | $112K |
| 2020 | 346 | $14K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 4,703 | 333 | $327K |
| 83970 | 314 | 188 | $0.00 | |
| 83540 | 252 | 152 | $0.00 | |
| 85048 | 112 | 62 | $0.00 | |
| 85041 | 200 | 112 | $0.00 | |
| 83550 | 252 | 152 | $0.00 | |
| A4657 | Syringe, with or without needle, each | 400 | 215 | $0.00 |
| 82728 | 310 | 188 | $0.00 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 24 | 12 | $0.00 |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 427 | 25 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 21 | 12 | $0.00 |